Reyes Jorge Alberto Cantú, Escurra Erik Antonio Mier, Rangel Joel Cázares, Ita Julieta Rodríguez De, Lindemann Jan Lammel, García Luis Francisco Rendón, López Boris José Chacón
Hospital Regional de Alta Especialidad Materno Infantil. Nuevo León, México.
Escuela de Medicina, Tecnológico de Monterrey, Monterrey. Nuevo León, México.
Bol Med Hosp Infant Mex. 2018;75(2):89-93. doi: 10.24875/BMHIM.M18000013.
Lymphatic vascular malformations (LVM) or formerly called lymphangiomas are congenital malformations present in about 1 out of 6000 to -16000 births. The most relevant classification system for lymphangioma management is based on the size of the cysts. Spontaneous resolution is uncommon; thus, expectant management is not recommended. The classic treatment is excisional surgery, but it can affect adjacent structures or have relapses, so, sclerosing substances like OK-432 are being studied. The majority of the studies are small in number of patients and are from Japan; the largest studies in Mexico are focused on specific lesions (macrocystic) or a determined anatomical region. To date, there are no studies of the population of the north of Mexico.
The experience with OK-432 was described through a retrospective, descriptive study in patients with LVM, from 2011 to 2016, in a reference hospital of northern Mexico.
A total of 26 patients with LVM were treated with OK-432. The majority of the lesions were macrocystic (69 %), microcystic (19 %) and mixed (12 %). From the total number of patients, 11 fully healed, and 72 % of the study population had >50 % reduction in lesion size, with only 2 applications. There were no recurrences. Complications were reported in 2 patients who had skin hyperpigmentation.
OK-432 probed to be an effective treatment for LVM in a reference hospital in the north of Mexico.
淋巴管畸形（LVM），以前称为淋巴管瘤，是一种先天性畸形，在每6000至16000例出生中约有1例出现。淋巴管瘤治疗最相关的分类系统基于囊肿大小。自然消退并不常见；因此，不建议采用观察等待的治疗方法。经典治疗方法是手术切除，但可能会影响相邻结构或复发，所以，像OK-432这样的硬化剂正在研究中。大多数研究的患者数量较少，且来自日本；墨西哥规模最大的研究集中在特定病变（大囊型）或特定解剖区域。迄今为止，墨西哥北部尚无相关人群研究。
通过对2011年至2016年在墨西哥北部一家参考医院就诊的淋巴管畸形患者进行回顾性描述性研究，描述了使用OK-432的经验。
共有26例淋巴管畸形患者接受了OK-432治疗。大多数病变为大囊型（69%）、微囊型（19%）和混合型（12%）。在所有患者中，11例完全治愈，72%的研究人群在仅进行2次治疗后病变大小缩小了50%以上。无复发情况。2例患者出现皮肤色素沉着等并发症。
在墨西哥北部的一家参考医院，OK-432被证明是治疗淋巴管畸形的有效方法。
